Celgene Reports Positive Results From Revlimid Trial
October 23 2018 - 6:01PM
Dow Jones News
By Stephen Nakrosis
Celgene Corporation (CELG) on Tuesday said results from an
open-label phase II/III National Clinical Trials Network study
showed single-agent Revlimid achieved a statistically significant
improvement in the primary endpoint of progression-free survival
compared to observation.
The study was led by the ECOG-ACRIN Cancer Research Group and
sponsored by the National Cancer Institute, part of the National
Institutes of Health. Revlimid was provided under a clinical trials
agreement with the NCI's Division of Cancer Treatment and
Diagnosis.
Based on the preliminary results of the study, safety was
consistent with the known safety profile of Revlimid.
"In multiple myeloma, there has been an important question
regarding the risks and benefits of treating patients with
smoldering myeloma. We believe that the properties of Revlimid
could play an important role in delaying the progression of
smoldering myeloma into active myeloma," said Jay Backstrom, chief
medical officer for Celgene.
The company also said Tuesday that Dr. Alise Reicin had been
named President, Global Clinical Development, effective November 1,
2018. In this role, Dr. Reicin will be responsible for all aspects
of mid- to late-stage clinical development across Celgene's
portfolio and will serve on the company's Executive Committee.
Dr. Reicin was most recently Senior Vice President and Head of
Global Clinical Development in Research and Development at EMD
Serono, the biopharmaceutical business of Merck KGaA, in Darmstadt,
Germany.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 23, 2018 17:46 ET (21:46 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2024 to May 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From May 2023 to May 2024